Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q3 FY2018 Earnings Presentation
21 slides from Jubilant Pharmova's earnings presentation, Jan 17, 2018
Slide 1: Financial Results Quarter Ended December 31, 2017
Financial Results Quarter Ended December 31, 2017
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : January, 17, 2017 Time : 05:00 pm IST Primary Number: +91 22 3938 1071 3940 3977 Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Local Access Number: Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers. USA: 1 866 746 2133 U
Slide 4: Q3'FY18 and 9M'FY18 Results Analysis
Q3’FY18 and 9M’FY18 Results Analysis 33
Slide 5: Income Statement – Q3'FY18
Income Statement – Q3’FY18 Particulars Q3'FY17 Q2'FY18 Q3'FY18 YoY Growth QoQ Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 1,458 1,642 2,068 42% 26% Pharmaceuticals 782 860 1,101 41% 28% Life Science Ingredients 633 738 922 46% 25% Drug Discovery Solutions 44 44 45 2% 2% Total E
Slide 6: Financial Highlights – Q3'FY18
Financial Highlights – Q3’FY18 • Consolidated revenue at Rs. 2,068 Crore, up 42% YoY and 26% QoQ • Pharmaceuticals revenue at Rs. 1,101 Crore, contributing 53% to the revenues, up 41% YoY and 28% QoQ • Life Science Ingredients revenue at Rs. 922 Crore, contributing 45% to the revenues, up 46% YoY an
Slide 7: Income Statement – 9M'FY18
Income Statement – 9M’FY18 Particulars 9M'FY17 9M'FY18 YoY Growth (Rs Crs) (%) Total Revenue from Operations (Net of Excise) 4,263 5,266 24% Pharmaceuticals 2,300 2,776 21% Life Science Ingredients 1,832 2,361 29% Drug Discovery Solutions 131 130 -1% Total Expenditure 3,223 4,205 30% Other Income 14
Slide 8: Financial Highlights – 9M'FY18
Financial Highlights – 9M’FY18 • Consolidated revenue at Rs. 5,266 Crore, up 24% YoY • Pharmaceuticals revenue at Rs. 2,776 Crore, up 21% YoY, contributing 53% to the revenues • LSI revenue at Rs. 2,361 Crore, up 29% YoY, contributing 45% to the revenues • Drug Discovery Solutions revenue at Rs. 130
Slide 9: Pharmaceuticals Segment Highlights
Pharmaceuticals Segment Highlights Region-wise Revenue (Rs crs) Q3'FY17 Q2'FY18 Q3'FY18 Mix % YoY % QoQ % ROW Europe &6.0%India International 745 831 1,067 97% 43% 28% Japan 3.1% North America 529 672 915 83% 73% 36% 7.8% Europe & Japan 138 86 85 8% -38% -1% ROW 79 72 66 6% -16% -8% North America 83
Slide 10: Pharmaceuticals Segment Highlights
Pharmaceuticals Segment Highlights • Rubyfill installation completed in three sites in the USA during Q3’FY18 • Received approval for Drax Exametazime during the year; Expect to launch in FY19 • Received USFDA approval for new pulmonary indication in Draximage DTPA in Q3’FY18 • Ramp up of CMO busine
Slide 11: Regulatory Status
Regulatory Status Regulatory Cadista Roorkee CMO / Allergy CMO JDI Montreal Nanjangud • All sites successfully Agency USA India Spokane Montreal Canada India inspected and fully compliant with USFDA Mar 2017 Mar 2017 Sep 2017 Dec 2016 Sep 2017 Oct 2017 (USA) regulations Oct 2017 Apr 2016 Oct 2017 •
Slide 12: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Product pipeline as on December 31, 2017 Dosage (Orals) Injectables Region Total Filings Approval Pending Total Filings Approval Pending US 86 56 30 12 10 2 Canada 22 22 - 13 13 0 Europe 100 95 5 10 10 0 ROW 687 490 197 44 40 4 Total 895 663 232 79 7
Slide 13: Portfolio of R&D products – Filings and Approvals
Portfolio of R&D products – Filings and Approvals Dosage (Orals) Filed 86 ANDAs in the US • 56 ANDAs have been approved and 30 ANDAs are pending approval • Filed 3 ANDAs in 9M’FY 18 Made 809 filings in ROW markets including Canada, Europe and Japan • 607 filings have been approved and 202 filing
Slide 14: LSI Segment Highlights
LSI Segment Highlights Region-wise Revenue (Rs crs) Q3'FY17 Q2'FY18 Q3'FY18 Mix % YoY % QoQ % ROW International 273 308 371 40% 36% 21% 14.0% Europe, Europe, North America and Japan 192 187 242 26% 27% 30% North India ROW 81 121 129 14% 58% 7% America and 59.7% Japan India 360 430 551 60% 53% 28% 26
Slide 15: LSI Segment Highlights
LSI Segment Highlights • Nutritional Products: • Received WHO GMP compliance certification for Vitamins which will help us increase our footprint in the premium food and multi-vitamin business, with better realizations • Prices maintained at healthy levels for the quarter • Life Science Chemicals: •
Slide 16: Drug Discovery Solutions Segment Highlights
Drug Discovery Solutions Segment Highlights ROW Region-wise Revenue (Rs crs) Q3'FY17 Q2'FY18 Q3'FY18 Mix % YoY % QoQ % 1.9% International 43 43 43 97% 0% 1% India North America 32 33 27 60% -17% -19% 2.6% Europe & Europe & Japan 10 8 16 35% 56% 91% Japan 35.2% North America ROW 1 1 1 2% -17% -39% 60
Slide 17: Expenditure Analysis – Q3'FY18
Expenditure Analysis – Q3’FY18 YoY QoQ % of % of Expenses (Rs Crs) Q3'FY17 % of Sales Q2'FY18 Q3'FY18 Growth Growth Sales Sales % % Material Cost and Change in Inventory 428 29% 556 34% 707 34% 65% 27% Purchases of stock-in-trade 61 4% 52 3% 79 4% 30% 53% Employee benefits expense 309 21% 369 22% 42
Slide 18: Expenditure Analysis – 9M'FY18
Expenditure Analysis – 9M’FY18 Expenses (Rs Crs) 9M'FY17 % of Sales 9M'FY18 % of Sales YoY Growth % Material Cost and Change in Inventory 1,266 30% 1,809 34% 43% Purchases of stock-in-trade 143 3% 169 3% 18% Employee benefits expense 906 21% 1,102 21% 22% Power and fuel expense 241 6% 313 6% 30% Oth
Slide 19: Debt Profile
Debt Profile Particulars 31-Mar-17 30-Sep-17 31-Dec-17 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 19 19 0 Subsidiaries 407 392 374 Total 426 411 374 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,241 1,214 1,227 Subsidiaries 82 96 101 Total 1,323 1,310 1,327 Gross Debt (Rs. Crs)
Slide 20: Outlook
Outlook Very robust business performance driven by Specialty Pharmaceuticals – Injectables and LSI segment. We are confident of delivering outstanding performance going forward in Q4’FY18 and FY19: • Specialty Pharmaceuticals - Injectables: • Continue to deliver exceptional performance in Radiopha
Slide 21: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 Ph: +91 22 6645 1209 E-mail: ravi.agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Sulakshana Mehrotra Jubilant Life Sciences Limited Perfect
Jubilant Life Sciences — Q3 FY2018 Earnings Presentation on 6ix